New treatment hope for prostate cancer

Feb 06, 2009

Scientists at Melbourne's Burnet Institute have developed a potential new treatment for patients with prostate cancer. An article, which described the invention, has recently been published in the prestigious international journal The Journal of Clinical Investigation.

Head of the Burnet Institute's Cancer Immunotherapy Laboratory, Associate Professor Pei Xiang Xing said his group has produced a monoclonal antibody to a unique tumour marker for the treatment of prostate cancer. The monoclonal antibody is directed at cancer-producing cells carrying the specific molecule known as PIM-1, which is responsible for cell survival, proliferation and differentiation. Over-expression of PIM-1 plays a critical role in the development, progression and metastasis of prostate cancer and other cancers such as leukaemia. The monoclonal antibody significantly inhibited cancer cell growth when used in laboratory models of prostate cancer.

Professor Xing's group demonstrated that the monoclonal antibody binds to PIM-1 present in cancer cells and creates a chain of events leading to the death of the cells. In particular, the therapeutic effect was improved by combination of the antibody with other drugs currently used to treat prostate cancer.

Prostate cancer is one of the most frequently diagnosed invasive cancers and the third leading cause of death in men worldwide. More than 3,000 men die each year from prostate cancer, equal to the number of women who die from breast cancer; and more than 18,000 new cases are diagnosed in Australia each year. A new strategy to treat prostate cancer is urgently needed as there is no efficient method to treat advanced prostate cancer.

Director of the Burnet Institute, Professor Brendan Crabb said that while the therapy was still in its early days this was the first time that researchers had found a treatment that targeted prostate cancer cells with a specific antibody to PIM-1 and which resulted in the death of the malignant cells and a reduction in tumour size.

"This is an exciting step in the development of new treatments for patients with prostate cancer with very promising laboratory-test results," Professor Crabb said.

While further laboratory research is still required to refine the treatment, it is expected that clinical trials of the new therapy will commence in the near future.

Source: Research Australia

Explore further: Global health experts call into question sub-Saharan cancer data

add to favorites email to friend print save as pdf

Related Stories

Potential new breathalyzer for lung cancer screening

Feb 18, 2015

Researchers from Chongqing University in China have developed a high sensitive fluorescence-based sensor device that can rapidly identify cancer related volatile organic compounds—biomarkers found exclusively in the exhaled ...

Johnson & Johnson tops 4Q earnings expectations

Jan 20, 2015

The strong dollar and stiff competition for some products squeezed Johnson & Johnson in the fourth quarter and it missed Wall Street expectations for revenue, triggering a rare sell-off of its shares.

Recommended for you

Deodorant use ok for radiotherapy patients

1 hour ago

Women undergoing radiotherapy for breast cancer can use deodorant without fear of increased underarm skin reaction, pain, itching or burning, research suggests.

Pancreatic cancer has four distinct types

2 hours ago

Researchers have found that pancreatic cancer can be split into four unique types, a discovery that could be used to improve treatments for the disease, according to a study published in Nature.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.